Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S filed an initial ownership report for its Chief Scientific Officer, detailing holdings of warrants and ordinary shares of Evaxion A/S. The filing shows direct ownership of 36,765 ordinary shares and multiple warrant series over additional ordinary shares at various exercise prices and expirations.
These warrants cover amounts such as 36,765 underlying shares at an exercise price of $0.74 expiring on December 21, 2026, and other grants with exercise prices including $0.10, $0.40, $0.75, $2.23, and $5.38 expiring on dates through 2036. One warrant position stems from a private placement that closed on December 21, 2023, and certain grants vest at a rate of 1/36 per month over 36 months from their initial exercise dates.
Evaxion A/S director Lars Holtug filed an initial ownership report showing his existing positions in ordinary shares and warrants. Indirectly through LH2022 ApS, he holds 258029 ordinary shares plus warrants over 73529 shares at an exercise price of 0.7400 and 92250 shares at 0.0590. He also directly holds several warrant series over 4583, 5000, 5000, 20000 and 25000 ordinary shares with exercise prices between 0.0700 and 5.3800 and expirations running to 2031-12-31. Some warrants stem from a private placement that closed on 2023-12-21 and a public offering that closed on 2025-01-31, with certain grants vesting monthly over 12 months from their initial exercise dates.
Evaxion A/S filed an initial insider ownership report detailing equity interests related to its ordinary shares. The filing lists warrants exercisable into 2,500,000 ordinary shares at an exercise price of $0.12 per share, expiring on December 31, 2031, with vesting at 1/36 per month over 36 months from the initial exercise date.
It also reports 2,286,150 ordinary shares held indirectly, noted as owned "By James Noble," who is identified in a footnote as the spouse of Dr. Tayton-Martin. The entry reflects holdings rather than new buy or sell transactions.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop vaccines, will present two scientific abstracts at the AACR Annual Meeting in San Diego on April 17-22, 2026. This update is furnished on a Form 6-K and incorporated into several of Evaxion’s U.S. registration statements.
One abstract covers new biomarker and immunogenicity data for EVX-01, a personalized cancer vaccine being evaluated in a phase 2 trial for advanced melanoma in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab). Each enrolled patient receives an individually designed vaccine based on their biology.
The second abstract discusses using AI-Immunology™ to identify endogenous retrovirus-derived neoantigens for personalized vaccines targeting glioblastoma, a severe brain cancer with limited treatment options. Evaxion will also take part in the AACR Oncology Industry Partnering event to explore potential business and scientific collaborations.
Evaxion A/S reported a much stronger 2025, combining major partnership wins with improved finances. Revenue rose to $7.5 million, mainly from MSD’s option exercise and a Gates Foundation grant, while the net loss narrowed to $7.7 million, an improvement of $2.9 million from 2024.
Cash and cash equivalents increased to $23.2 million as of December 31, 2025, and total equity improved to $17.0 million from a negative balance a year earlier, helped by the MSD deal and an EIB debt‑to‑equity conversion. Management expects operational cash burn of about $14 million in 2026 and says current cash can fund operations into the second half of 2027. Evaxion also licensed infectious disease vaccine candidate EVX‑B3 to MSD, with $7.5 million received and up to $592 million in potential milestones, advanced its AI‑Immunology™ platform, and outlined 2026 milestones across oncology, infectious disease and a new autoimmune disease initiative.
Evaxion A/S reported a much stronger 2025, combining major partnership wins with improved finances. Revenue rose to $7.5 million, mainly from MSD’s option exercise and a Gates Foundation grant, while the net loss narrowed to $7.7 million, an improvement of $2.9 million from 2024.
Cash and cash equivalents increased to $23.2 million as of December 31, 2025, and total equity improved to $17.0 million from a negative balance a year earlier, helped by the MSD deal and an EIB debt‑to‑equity conversion. Management expects operational cash burn of about $14 million in 2026 and says current cash can fund operations into the second half of 2027. Evaxion also licensed infectious disease vaccine candidate EVX‑B3 to MSD, with $7.5 million received and up to $592 million in potential milestones, advanced its AI‑Immunology™ platform, and outlined 2026 milestones across oncology, infectious disease and a new autoimmune disease initiative.
Evaxion A/S files its 2025 annual report, highlighting a development-stage biotech business built on its AI-Immunology™ platform and focused on cancer and infectious disease vaccines. Financial statements are prepared under IFRS in USD, with DKK as functional currency.
As of December 31, 2025, Evaxion had 417,010,756 ordinary shares outstanding and an accumulated deficit of $126.2 million, reflecting years of operating losses and limited revenue. In 2025, Merck (MSD) licensed vaccine candidate EVX-B3, providing a $7.5 million cash payment and potential future milestones and royalties.
The company reports significant ongoing risks: it expects continued losses, depends on raising substantial additional capital, and relies on partners and third parties for late-stage development, manufacturing, and commercialization. Its AI-driven discovery approach, while central to the strategy, is described as novel, unproven, and subject to scientific, regulatory, and commercialization uncertainties.
Evaxion A/S files its 2025 annual report, highlighting a development-stage biotech business built on its AI-Immunology™ platform and focused on cancer and infectious disease vaccines. Financial statements are prepared under IFRS in USD, with DKK as functional currency.
As of December 31, 2025, Evaxion had 417,010,756 ordinary shares outstanding and an accumulated deficit of $126.2 million, reflecting years of operating losses and limited revenue. In 2025, Merck (MSD) licensed vaccine candidate EVX-B3, providing a $7.5 million cash payment and potential future milestones and royalties.
The company reports significant ongoing risks: it expects continued losses, depends on raising substantial additional capital, and relies on partners and third parties for late-stage development, manufacturing, and commercialization. Its AI-driven discovery approach, while central to the strategy, is described as novel, unproven, and subject to scientific, regulatory, and commercialization uncertainties.
Evaxion A/S reported a slight delay in filing and publishing its 2025 annual report because of unforeseen technical issues at external vendors related to regulatory filing requirements. The report itself has been finalized and will be filed and published as soon as the technical problems are resolved.
As a result of this delay, the conference call and webcast planned for today have been moved to Friday, March 6 at 8.30 ET / 14.30 CET. Evaxion is a clinical-stage TechBio company that uses its AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases.
Evaxion A/S reported a slight delay in filing and publishing its 2025 annual report because of unforeseen technical issues at external vendors related to regulatory filing requirements. The report itself has been finalized and will be filed and published as soon as the technical problems are resolved.
As a result of this delay, the conference call and webcast planned for today have been moved to Friday, March 6 at 8.30 ET / 14.30 CET. Evaxion is a clinical-stage TechBio company that uses its AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, will provide a business update and report its full year 2025 financial results on March 5, 2026 before the opening of the Nasdaq Capital Market.
Executive management will host a conference call and webcast the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Participants can register in advance to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website after the event.
Evaxion A/S filed a Form 6-K describing two February 2026 warrant grants under its equity incentive framework. On February 5, the board granted 6,544,725 warrants to board members, management and employees, each allowing subscription for one ordinary share at USD 0.087 per share, subject to a DKK 0.25 minimum and adjustment mechanisms. Most of these warrants vest monthly from January 1, 2026, with a portion fully vested at grant. On February 16, the board granted a further 2,500,000 warrants to board members, management, employees and advisors at USD 0.115 per share, also with a DKK 0.25 floor and similar adjustment provisions, vesting monthly from November 1, 2025. Following these grants, additional warrants over nominal DKK 6,857,257 of ordinary shares remain available for future awards, and the Articles of Association were amended to reflect the new warrant programs.
Evaxion A/S reports that it is expanding its proprietary AI-Immunology™ platform beyond cancer and infectious disease to include autoimmune diseases as a third core focus area. The company plans to expand and train AI-Immunology™ for autoimmune applications during the second half of 2026, aiming to discover precision treatments that target underlying disease mechanisms rather than just symptoms. Management highlights that autoimmune conditions carry high unmet medical need and offer partnership potential across all stages of drug development.
Evaxion states that the work needed to adapt its platform to autoimmune diseases is already reflected in its cashflow outlook and does not change its expected cash runway into the second half of 2027. The company also outlines 2026 milestones, including additional biomarker and immunogenicity data for EVX-01 in the first half of 2026, and in the second half of 2026 phase 2 three-year efficacy data for EVX-01, a regulatory filing for a phase 1 trial of EVX-04, and design and preclinical validation of antigens for EVX-B4.